STAR-LLD seeks to replace standard care for blood cancers
Starton Therapeutics announced it has dosed the first patient in its Phase IIa study evaluating STAR-LLD for the treatment of relapsed/refractory multiple myeloma (RRMM). STAR-LLD is a continuous delivery lenalidomide (LLD) in development seeking to expand and replace the standard-of-care for the most common blood cancers, multiple… Read More